Ludovic Fenaux, senior vice-president at Vertex International, said the company was “delighted” and thanked patients for “their contribution in describing the value that these innovative medicines bring to patients”.
The deal also includes a commitment by all parties to work together on a path towards rapid access for all eligible patients for future treatments for the condition.
A spokesperson for NICE said the organisation “is grateful to NHS England, Vertex and the patient groups for working so tirelessly to provide the right evidence to allow a fair price to be agreed” for the NHS and taxpayers.
David Ramsden, chief executive of Cystic Fibrosis Trust, called the deal a “fantastic moment”.
“We should not forget though, that these treatments are not a cure and simply don’t work for some people. With the support of our incredible community, clinicians and researchers, a lot has been achieved, but we know there is still lots more to do,” he added.
